EU Approves Enhertu-Pertuzumab Combination for First-Line Breast Cancer Care

The European Union has approved a combination therapy pairing Enhertu with pertuzumab for the first-line treatment of patients with HER2-positive breast cancer. The regulatory decision opens the door for clinicians across the bloc to prescribe the dual-agent regimen as an initial intervention for this aggressive subtype of breast cancer, moving advanced targeted therapies into front-line treatment protocols.

HER2-positive breast cancers are historically aggressive, making early, highly targeted intervention critical for long-term patient survival. Authorising a combination regimen for newly diagnosed cases provides European oncologists with a potent new option before the disease advances or builds resistance to single-agent treatments, shifting the baseline clinical standard for first-line oncology care.

Centralised EU approvals reflect one of the single market's quiet successes: a single authorization legally opens the market across all 27 member states simultaneously. However, regulatory harmonization stops at the clinic door. While Brussels grants market access, healthcare delivery remains strict national turf, leaving each EU capital to decide how quickly the therapy enters local practice.

The decision now shifts to national health ministries and pricing committees across Europe. Individual member states will conduct their own health economics evaluations to decide whether public health systems will reimburse the combination therapy. Patients in countries with swift reimbursement mechanisms will likely gain access first, while others face the standard waiting period for national budget negotiations.